{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:28:34Z","timestamp":1773235714503,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1023\/a:1008397109048","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"163-167","source":"Crossref","is-referenced-by-count":24,"title":["Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study"],"prefix":"10.1016","volume":"11","author":[{"given":"J.","family":"Janinis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Samelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Skarlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Papagianopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008397109048_bb0005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","article-title":"Modulation of fluorouracil with leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate","volume":"10","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008397109048_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1989.7.4.425","article-title":"A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma, a Mid-Atlantic Oncology Program study","volume":"7","author":"Lokich","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008397109048_bb0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.1991.9.4.625","article-title":"A phase II of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal cancer","volume":"9","author":"Ardalan","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008397109048_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0753-3322(89)90004-8","article-title":"Antitumor activity of a new platinum complex, oxalato(trans-1-1,2-diaminocyclohexane)platinum(II): New experimental data","volume":"43","author":"Tashiro","year":"1989","journal-title":"Biomed Pharmacother"},{"key":"10.1023\/A:1008397109048_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase II studies of oxaliplatin(L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008397109048_bb0030","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00001813-199710000-00009","article-title":"Buquet-Fagot C, Djelloul S et al. Antitumor activity of oxaliplatin in combination with fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breats and ovarian cancers","volume":"8","author":"Raymond","year":"1997","journal-title":"Anti-Cancer Drugs"},{"key":"10.1023\/A:1008397109048_bb0035","first-page":"95","article-title":"New Drugs in colorectal cancer: A review of antitumor activity and cross resistance patterns of topoisomerase I inhibitors, thymidylate synthetase inhibitors, and oxaliplatin","volume":"21","author":"Harsink","year":"1998","journal-title":"Onkologie"},{"key":"10.1023\/A:1008397109048_bb0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000421-199806000-00015","article-title":"Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil","volume":"21","author":"DeBraud","year":"1998","journal-title":"Am J Clin Oncol. Cancer Clin Trials"},{"key":"10.1023\/A:1008397109048_bb0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0959-8049(96)00370-X","article-title":"Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer","volume":"33","author":"DeGramont","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008397109048_bb0050","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0959-8049(99)00149-5","article-title":"Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)","volume":"9","author":"Maindrault-Goebel","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008397109048_bb0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1023\/A:1008397109048_bb0105","series-title":"Categorical Data Analysis. Inference for Two-Way Contingency Tables","first-page":"59","author":"Agresti","year":"1990"},{"key":"10.1023\/A:1008397109048_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1023\/A:1008397109048_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00684890","article-title":"Phase I study of oxaliplatin in patients with advanced cancer","volume":"25","author":"Extra","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1023\/A:1008397109048_bb0070","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: A review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008397109048_bb0075","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1023\/A:1008475122124","article-title":"Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluoroouracil regimen","volume":"9","author":"Andre","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008397109048_bb0080","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1023\/A:1008397109048_bb0085","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1200\/JCO.1996.14.11.2950","article-title":"Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and Leucovorin in patients with metastatic colorectal cancer","volume":"14","author":"Bertheault-Cvitkovic","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008397109048_bb0090","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008397109048_bb0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00008571-199412000-00002","article-title":"Potential importance of dihydropyrimidine dehydrogenase in cancer chemotherapy","volume":"4","author":"Milano","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1023\/A:1008397109048_bb0100","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmakokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosing","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419548992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419548992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/2\/163\/19478180\/11-2-163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:13:38Z","timestamp":1582182818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419548992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["S0923753419548992"],"URL":"https:\/\/doi.org\/10.1023\/a:1008397109048","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}